Team:UIUC Illinois/project-overview

From 2012e.igem.org

Revision as of 16:44, 27 October 2012 by Adi25 (Talk | contribs)

Header

The Company

YOU HAVE 960 PIXELS WIDTH TO PLAY WITH FOR WHATEVER YOU WANT TO EMBED! Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas metus nulla, commodo a sodales sed, dignissim pretium nunc. Nam et lacus neque. Sed volutpat ante id mauris laoreet vestibulum. Nam blandit felis non neque cursus aliquet. Morbi vel enim dignissim massa dignissim commodo vitae quis tellus. Nunc non mollis nulla. Sed consectetur elit id mi consectetur bibendum. Ut enim massa, sodales tempor convallis et, iaculis ac massa. Etiam suscipit nisl eget lorem pellentesque quis iaculis mi mattis. Aliquam sit amet purus lectus. Maecenas tempor ornare sollicitudin.

Executive Summary

The Company

Illinois Synth was formed in June 2012 to develop, market, and license products intended to further the progress of synthetic biology. Our founding team is comprised of six University of Illinois undergraduate students from a variety of backgrounds including bioengineering, biochemistry, molecular biology, agricultural engineering and chemical engineering. Brought together initially by the desire to work with synthetic biology in the context of the International Genetically Engineered Machines (iGEM) competition, we are now in the process of commercializing our research.

The Products

The two product lines being developed by Illinois Synth are as follows:

The Market

Ever since the discovery of restriction enzymes in 1978, a new era of synthetic biology was ushered in, an era in which scientific discovery would meet engineering, and promised the ability to eventually control and modulate gene expression. Illinois Synth has a deep confidence not only in the growth of synthetic biology as an industry, but in the growing demand for technologies that will allow the modulation of gene expression in RNA. Such tools currently take the form of RNA recognition motifs, K Homology proteins, and CCCH Zinc Finger proteins that in many cases do not exhibit sequence specific binding, or are unable to be programmed to recognize specific, desired ssRNA sequences. With regard to the use of an in vivo enzymatic cascade to produce piceatannol, our analysis has shown that such a method would be faster, more efficient, and lower cost than chemical synthesis of the compound, which is the only current mode of production.

Competitive Analysis

Our competitive analysis was broken into two components:

Market Penetration

Cras luctus fringilla odio vel hendrerit. Cras pulvinar auctor sollicitudin. Sed lacus quam, sodales sit amet feugiat sit amet, viverra nec augue. Sed enim ipsum, malesuada quis blandit vel, posuere eget erat. Sed a arcu justo. Integer ultricies, nunc at lobortis facilisis, ligula lacus vestibulum quam, id tincidunt sapien arcu in velit. Vestibulum consequat augue et turpis condimentum mollis sed vitae metus. Morbi leo libero, tincidunt lobortis fermentum eget, rhoncus vel sem. Morbi varius viverra velit vel tempus. Morbi enim turpis, facilisis vel volutpat at, condimentum quis erat. Morbi auctor rutrum libero sed placerat. Etiam ipsum velit, eleifend in vehicula eu, tristique a ipsum. Donec vitae quam vel diam iaculis bibendum eget ut diam. Fusce quis interdum diam. Ut urna justo, dapibus a tempus sit amet, bibendum at lectus. Sed venenatis molestie commodo.

Marketing

Proin nec turpis eget dolor dictum lacinia. Nullam nunc magna, tincidunt eu porta in, faucibus sed magna. Suspendisse laoreet ornare ullamcorper. Nulla in tortor nibh. Pellentesque sed est vitae odio vestibulum aliquet in nec leo.

Operating Systems

Proin nec turpis eget dolor dictum lacinia. Nullam nunc magna, tincidunt eu porta in, faucibus sed magna. Suspendisse laoreet ornare ullamcorper. Nulla in tortor nibh. Pellentesque sed est vitae odio vestibulum aliquet in nec leo.

Financial Plan

Proin nec turpis eget dolor dictum lacinia. Nullam nunc magna, tincidunt eu porta in, faucibus sed magna. Suspendisse laoreet ornare ullamcorper. Nulla in tortor nibh. Pellentesque sed est vitae odio vestibulum aliquet in nec leo.

Growth Plan

Proin nec turpis eget dolor dictum lacinia. Nullam nunc magna, tincidunt eu porta in, faucibus sed magna. Suspendisse laoreet ornare ullamcorper. Nulla in tortor nibh. Pellentesque sed est vitae odio vestibulum aliquet in nec leo.

Investor Highlights

Proin nec turpis eget dolor dictum lacinia. Nullam nunc magna, tincidunt eu porta in, faucibus sed magna. Suspendisse laoreet ornare ullamcorper. Nulla in tortor nibh. Pellentesque sed est vitae odio vestibulum aliquet in nec leo.

Retrieved from "http://2012e.igem.org/wiki/index.php/Team:UIUC_Illinois/project-overview"